+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ASTRAZEN

AstraZeneca Pharma India Share Price

 

 

AstraZeneca Pharma India live price: ₹8236. It opened at ₹8,313 vs previous close ₹8,311; intraday high/low: ₹8,364/₹8,214. The 50 & 200 DMA stand at ₹8,423.81/₹8,527.20.

AstraZeneca Pharma India Performance

  • Today's Low
  • ₹8,214
  • Today's High
  • ₹8,364
  • 52 Week Low
  • ₹7,552
  • 52 Week High
  • ₹9,850
  • Open Price₹8,313
  • Previous Close₹8,311
  • Volume1,502
  • 50 DMA₹8,423.81
  • 100 DMA₹8,492.82
  • 200 DMA₹8,527.20

AstraZeneca Pharma India Chart

Investment Returns

  • Over 1 Month -4.23%
  • Over 3 Month + 5.22%
  • Over 6 Month -2.39%
  • Over 1 Year -9.52%

Smart Investing Starts Here Start SIP with AstraZeneca Pharma India for Steady Growth!

Invest Now

AstraZeneca Pharma India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 109.8
  • PEG Ratio
  • 1.8
  • Market Cap Cr
  • 20,590
  • P/B Ratio
  • 23.6
  • Average True Range
  • 216.93
  • EPS
  • 76.57
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -50.6
  • RSI
  • 44.36
  • MFI
  • 38.16

Latest Stock News Updates

`Our goal to bring innovation faster to India:' AstraZeneca India-chief

AstraZeneca is focused broadly on oncology (increasingly our largest segment globally and in India); biopharmaceuticals (cardiovascular, renal, respiratory, immunology, and vaccines); and rare diseases.

India could be on the radar for AstraZeneca's oral GLP-1 drug: MD

AstraZeneca's MD hints at India's potential inclusion in global trials for its promising oral GLP-1 weight loss and diabetes drug.

AstraZeneca Pharma shares slip 6% on posting 23% fall in Q4 profit YoY

In the March quarter, AstraZeneca Pharma reported a 23 per cent year-on-year (Y-o-Y) decline in consolidated net profit to 44.9 crore, from 58.25 crore a year ago

AstraZeneca Pharma India Financials

AstraZeneca Pharma India Technicals

EMA & SMA

Current Price
₹8,236.00
-74.5 (-0.9%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹8,358.70
  • 50 Day
  • ₹8,423.80
  • 100 Day
  • ₹8,492.80
  • 200 Day
  • ₹8,527.20

Resistance and Support

8271.33 Pivot Speed
  • R3 8,478.67
  • R2 8,421.33
  • R1 8,328.67
  • S1 8,178.67
  • S2 8,121.33
  • S3 8,028.67

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

AstraZeneca Pharma India Ltd. is a global, science-led pharmaceutical company dedicated to transforming healthcare through innovative medicines in oncology, biopharmaceuticals, and rare diseases. it focuses on improving patient outcomes and advancing healthcare worldwide.

Astrazeneca Pharma India has an operating revenue of Rs. 2,275.58 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 11% is healthy, ROE of 21% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 54 which is a POOR score indicating inconsistency in earnings, a RS Rating of 46 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 48 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

AstraZeneca Pharma India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-26 Audited Results & Final Dividend
2026-02-11 Quarterly Results
2025-11-07 Quarterly Results
2025-08-14 Quarterly Results
2025-05-30 Audited Results & Dividend
Date Purpose Remarks
2025-07-18 FINAL Rs.32.00 per share(1600%)Dividend
2024-07-05 FINAL Rs.24.00 per share(1200%)Dividend
2023-07-14 FINAL Rs.16.00 per share(800%)Dividend
2022-07-08 FINAL Rs.8.00 per share(400%)Final Dividend
2021-08-20 INTERIM Rs.2.00 per share(100%)Interim Dividend
View AstraZeneca Pharma India Dividend History Arrow

AstraZeneca Pharma India Shareholding Pattern

75%
5.66%
0.06%
2.78%
0%
13.88%
2.62%

AstraZeneca Pharma India FAQs

AstraZeneca Pharma India share price is ₹8,236 As on 07 July, 2026 | 03:50

The Market Cap of AstraZeneca Pharma India is ₹20590 Cr As on 07 July, 2026 | 03:50

The P/E ratio of AstraZeneca Pharma India is 109.8 As on 07 July, 2026 | 03:50

The PB ratio of AstraZeneca Pharma India is 23.6 As on 07 July, 2026 | 03:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23